Sign in Subscribe
Diseases

Pulmonary Complications in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation: A Major Cause of Morbidity

Strategic Insights

— 1 min read

Researchers at the First Affiliated Hospital of Shandong First Medical University published a new study on the pulmonary complications that arise after pediatric allogeneic hematopoietic stem cell transplantation (allo-HSCT). The study found that pulmonary complications are a significant cause of morbidity in children undergoing allo-HSCT, particularly those with malignant diseases. The researchers analyzed the longitudinal pulmonary function test trajectories and early predictors of dysfunction in 233 children undergoing their first allo-HSCT.

Key Takeaways:

  • The study found that pulmonary complications are a major cause of morbidity following pediatric allo-HSCT, particularly in children with malignant diseases.
  • Children with malignant diseases exhibited significantly slower FEV1 recovery, greater severity of Restrictive Ventilatory Disorders (RVD), and higher cumulative incidences of Obstructive Ventilatory Disorders (OVD) and RVD compared to those with benign diseases.
  • The malignant group also had significantly higher rates of acute GVHD and chronic GVHD, which were associated with poorer pulmonary function outcomes.
  • The researchers identified 3-month PFT values and GVHD as early predictors of pulmonary dysfunction.
  • The study highlights the need for routine, stratified longitudinal monitoring to facilitate early risk stratification and intervention.

Statistics:

  • 233 children underwent their first allo-HSCT in the study.
  • 142 children had benign diseases (acquired aplastic anemia), while 91 had malignant diseases (leukemia/lymphoma).
  • The median follow-up time was 33.1 months.
  • The malignant group exhibited significantly slower FEV1 recovery, with a mean FEV1 value of 71.2% at 6 months, compared to 84.5% in the benign group.
  • The cumulative incidences of OVD and RVD were significantly higher in the malignant group, with HRs of 3.34 (P = 0.013) and 2.16 (P = 0.013), respectively.

Sources:

  • Comparative longitudinal analysis of pulmonary function post-pediatric Allo-HSCT: benign vs. malignant diseases and early predictors. Annals of Hematology, 2025.
  • NewsRx. New Pediatrics Study Findings Have Been Reported from First Affiliated Hospital of Shandong First Medical University (Comparative longitudinal analysis of pulmonary function post-pediatric Allo-HSCT: benign vs. malignant diseases and early ...). Health & Medicine Week. August 29, 2025; p 451.

Read more